CJC-1295 With DAC

CJC-1295 With DAC is a synthetic peptide derived from growth hormone–releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone secretion by acting on GHRH receptors in the anterior pituitary. The addition of a Drug Affinity Complex (DAC) allows the peptide to bind to circulating plasma proteins, significantly extending its biological half-life compared to native GHRH.

Research on CJC-1295 With DAC focuses on its ability to produce sustained, pulsatile growth hormone release, supporting physiological growth hormone rhythms rather than direct hormone replacement. This makes it a valuable research tool for studying growth hormone regulation, metabolic signaling, tissue repair processes, and age-related endocrine decline.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The DAC (Drug Affinity Complex) technology in CJC-1295 enables covalent binding to endogenous albumin following injection, dramatically extending the half-life to 6–8 days compared to minutes for native GHRH. This sustained elevation of GH and IGF-1 has been studied for effects on lean body mass, fat metabolism, and recovery processes. Research has compared pulsatile vs. sustained GH secretion profiles in the context of therapeutic and performance research (Teichman et al., 2006 — Journal of Clinical Endocrinology & Metabolism).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling. Store at -20°C. See also: CJC-1295 No DAC 10 mg, Ipamorelin 10 mg, Sermorelin 5 mg